For patients with advanced NSCLC stage, promising results were reported on the combination of metformin with chemotherapy, albeit with underpowered samples of 14, 25 and 30 patients.22–24 For patients with advanced disease and epidermal growth factor receptor (EGFR) mutations, two trials reported conflicting results. This evidence concerns the gene EGFR and non-small cell lung carcinoma.